Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma

Who May Qualify: Who May Qualify: - Performance Status Score 0-1 points. - Non-keratinized carcinoma of the nasopharynx (differentiated or undifferentiated, i.e., WHO type II or III) confirmed histologically and/or cytologically. - According to the UICC/AJCC eighth edition staging, the patient is defined as T1N0M0 stage I. - your organs (liver, kidneys, etc.) are working well enough based on blood tests: WBC ≥ 4×10\^9 /L, NEUT ≥ 2×10\^6 /L, HGB ≥ 9 g/dL, PLT count ≥ 100×10\^9/L, TBIL ≤1.5 ULN, ALT ≤3 ULN, AST ≤3 ULN, ALP ≤3 ULN, ALB ≥ 3 g/dL, INR or APTT≤1.5 ULN, Scr ≤1.5 ULN or Ccr ≥ 60 mL/min. - Informed Concent signed with willingness to obey the follow-up, treatment, examination and any other programs according to the research protocol. Who Should NOT Join This Trial: - Diagnosed as recurrent or distant metastatic nasopharyngeal carcinoma or together with any other malignancy. - Suffering severe organ dysfunction or physical disorder which could not tolerate surgery or radiotherapy. - Unable to cooperate with regular follow-up due to psychological, social, domestic or geological reasons. - During pregnancy or lactation. - Other patients that the chief physician considered as illegal for this trial. Always talk to your doctor about whether this trial is right for you.